Partnering To leverage its existing programs and to strengthen the maturity of its pipeline, Panoptes Pharma has implemented a comprehensive partnering and in-/out-licensing strategy. Panoptes will partner its projects with small and large pharmaceutical or biotech companies. Please contact us for further information.
4SC AG 4SC AG, based in Planegg-Martinsried near Munich, Germany, focuses on the clinical development of novel small molecule drugs that target key mechanisms of cancer development, such as histone deacetylases (HDAC). Researchers at 4SC previously also discovered PP-001 through its virtual screening approach followed by classical medicinal chemistry optimization. All rights in PP-001 and its chemical derivatives were transferred to Panoptes in year 2013.